---
title: "Double the ChiNext, amplify A-share power"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39605390.md"
description: "$Boshi China ChiNext Index Daily Leveraged (2X) Product (07234.HK)$ChiNext Index (399006.SZ) The ChiNext Index has gained +2.89% year-to-date.List of the top 20 heavyweight stocks in the Shenzhen ChiNext market: Investment involves risks. Past investment performance may not be indicative of future results. Investors should not base their investment decisions solely on the information contained herein. The above information is for reference only and does not constitute and should not be considered as an offer to subscribe to or sell to anyone. Investors should read the relevant fund's prospectus and product key facts statement in detail before making any investment decisions..."
datetime: "2026-03-30T02:37:39.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39605390.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39605390.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39605390.md)
author: "[博时国际](https://longbridge.com/en/profiles/16136055.md)"
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/39605390.md) | [繁體中文](https://longbridge.com/zh-HK/topics/39605390.md)


# Double the ChiNext, amplify A-share power

[$Boshi China GEM Index Daily Leveraged (2X) Product (07234.HK)](https://longbridge.com/quote/07234.HK)[$ChiNext Index (399006.SZ)](https://longbridge.com/quote/399006.SZ)The ChiNext board has gained +2.89% year-to-date.

Performance overview of the top 20 weighted stocks on the Shenzhen ChiNext board:

Investment involves risks. Past investment performance is not necessarily indicative of future performance. Investors should not base their investment decisions solely on this information provided. The above information is for reference only and does not constitute and should not be considered as an offer to subscribe for or sell to any person. Before making any investment decision, investors should read in detail the relevant fund's constitutive documents and product key facts statement, including the product features and risk factors contained therein. Investors should consider whether the product is suitable for them based on their own investment experience, investment objectives, financial situation, and risk tolerance. If necessary, seek independent professional advice. The above information has not been reviewed by the Securities and Futures Commission of Hong Kong.

Issued by: Bosera International. No part of this document or any information contained herein may be photocopied, distributed, or reproduced without the consent of Bosera International.[$Contemporary Amperex Technology (300750.SZ)](https://longbridge.com/quote/300750.SZ)[$East Money Information (300059.SZ)](https://longbridge.com/quote/300059.SZ)[$Inovance Technology (300124.SZ)](https://longbridge.com/quote/300124.SZ)[$Zhongji Innolight (300308.SZ)](https://longbridge.com/quote/300308.SZ)[$Mindray Medical (300760.SZ)](https://longbridge.com/quote/300760.SZ)[$Eoptolink Technology (300502.SZ)](https://longbridge.com/quote/300502.SZ)[$Sungrow Power Supply (300274.SZ)](https://longbridge.com/quote/300274.SZ)[$Wens Foodstuff Group (300498.SZ)](https://longbridge.com/quote/300498.SZ)

### Related Stocks

- [XL2 BOS CHINEXT (07234.HK)](https://longbridge.com/en/quote/07234.HK.md)
- [ChiNext (399006.CN)](https://longbridge.com/en/quote/399006.CN.md)
- [CATL (03750.HK)](https://longbridge.com/en/quote/03750.HK.md)
- [CATL (300750.CN)](https://longbridge.com/en/quote/300750.CN.md)
- [EASTMONEY (300059.CN)](https://longbridge.com/en/quote/300059.CN.md)
- [Inovance (300124.CN)](https://longbridge.com/en/quote/300124.CN.md)
- [Zhongji Innolight (300308.CN)](https://longbridge.com/en/quote/300308.CN.md)
- [Mindray (300760.CN)](https://longbridge.com/en/quote/300760.CN.md)
- [Contemporary Amperex Technology Co., Limited (HCCD.SG)](https://longbridge.com/en/quote/HCCD.SG.md)